Related Experiment Video
Updated: Aug 29, 2026
Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation
Published on: December 25, 2017
Testing for HER-2/neu in breast cancer: is fluorescence in situ hybridization superior in predicting outcome?
1PhenoPath Laboratories, 551 North 34th Street, Suite 100, Seattle, WA 98103, USA.
Abstract:
Testing for alterations in HER-2/neu in breast cancer has become increasingly popular in recent years, particularly with the recent development of a humanized antiHER-2/neu monoclonal antibody, trastuzumab, which is currently being employed in conjunction with cytotoxic chemotherapy to treat metastatic breast cancer in patients whose tumors exhibit this HER-2/neu alteration. Controversy exists not only on the optimal method of laboratory testing for this HER-2/neu alteration (i.e., fluorescence in situ hybridization (FISH) versus immunohistochemistry (IHC) versus others), but also on the type of reagents used for a given method. A plethora of published studies on tissue-based HER-2/neu testing has recently appeared in many peer-reviewed journals; many have concluded that IHC could be used as a first-line screening test, with the recommendation of FISH to confirm indeterminate results. In contrast to these studies, a recent study by Pauletti et al. showed that HER-2/neu testing by IHC does not predict clinical outcome as accurately as does FISH. This commentary discusses the findings of this study, within a broader review of critical issues relating to HER-2/neu testing in breast cancer.
Insights
Accurate HER-2/neu testing is crucial for breast cancer treatment. Fluorescence in situ hybridization (FISH) may be more reliable than immunohistochemistry (IHC) for predicting patient outcomes.
Area of Science:
- Oncology
- Molecular Diagnostics
- Biomarker Analysis
Background:
- HER-2/neu alterations are key targets in metastatic breast cancer treatment, particularly with anti-HER-2/neu therapies like trastuzumab.
- The choice of testing methodology, including fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC), for HER-2/neu alterations remains a subject of debate.
- Standardized and validated testing protocols are essential for effective patient management.
Discussion:
- This commentary critically evaluates recent findings suggesting FISH may offer superior predictive accuracy for clinical outcomes compared to IHC in HER-2/neu testing.
- It addresses the ongoing controversy regarding optimal laboratory testing methods and reagent choices for detecting HER-2/neu alterations.
- The reliability of IHC as a primary screening tool versus FISH for confirmation is discussed in light of conflicting study results.
Key Insights:
- Recent research indicates that HER-2/neu testing by IHC may not predict clinical outcomes as accurately as FISH.
- FISH is often recommended for confirming indeterminate IHC results, but its superior predictive value warrants further consideration.
- Discrepancies in testing methodologies can impact treatment decisions and patient prognosis.
Outlook:
- Further research is needed to establish definitive guidelines for HER-2/neu testing in breast cancer.
- Standardization of FISH and IHC protocols is crucial for consistent and reliable diagnostic results.
- Optimizing HER-2/neu testing strategies will enhance the efficacy of targeted therapies and improve patient outcomes.
More Related Videos
03:55Robust Detection of Gene Amplification in Formalin-Fixed Paraffin-Embedded Samples by Fluorescence In Situ Hybridization
Published on: July 12, 2024
08:28Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
